Characteristics | Person-months | Number of events | Incidence density per 1000 person-months (95% CI) |
---|---|---|---|
Baseline age in year (n = 937) | |||
18–25 | 3888 | 67 | 17.2 (13.6, 21.9) |
26–30 | 6174 | 76 | 12.3 (9.8, 15.4) |
31–40 | 8610 | 111 | 12.9 (10.7, 15.5) |
41–50 | 3042 | 29 | 9.5 (6.6, 13.7) |
51–71 | 1470 | 6 | 4.2 (1.8, 9.1) |
Sex (n = 937) | |||
Female | 12,630 | 195 | 15.5 (13.5, 17.8) |
Male | 10,554 | 94 | 8.9 (7.3, 10.9) |
Residence | |||
Bahir Dar and neighboring towns | 15,552 | 234 | 15.1 (13.2, 17.1) |
Others | 7632 | 55 | 7.2 (5.5, 9.4) |
Baseline functional status (n = 937) | |||
Working | 17,466 | 220 | 12.6 (11.0, 14.4) |
Ambulatory | 4830 | 61 | 12.6 (9.8, 16.2) |
Bedridden | 888 | 8 | 9.0 (4.5, 18.0) |
Baseline WHO clinical stage (937) | |||
Stage I | 1200 | 13 | 10.8 (6.3, 18.7) |
Stage II | 3768 | 35 | 9.3 (6.7, 12.9) |
Stage III | 1598 | 211 | 13.2 (11.5, 15.1) |
Stage IV | 2232 | 30 | 13.4 (9.4, 19.2) |
First treatment class (n = 1196) | |||
AZT-3TC | 14,514 | 166 | 11.4 (9.8, 13.3) |
D4t-3TC | 804 | 11 | 13.7 (7.6, 24.7) |
D4t (30) | 7866 | 112 | 14.2 (11.8,17.1) |
Baseline CD4 count in cells/mm3 (n = 1196) | |||
<200 | 19,848 | 192 | 9.7 (8.4, 11.1) |
200–349 | 3246 | 93 | 28.7 (23.3, 35.1) |
350–499 | 23,184 | 4 | 44.4 (16.7, 118.5) |